Provided by Tiger Fintech (Singapore) Pte. Ltd.

Agree

76.01
-1.0100-1.31%
Post-market: 76.010.00000.00%17:28 EDT
Volume:1.58M
Turnover:120.28M
Market Cap:8.14B
PE:42.70
High:77.16
Open:77.03
Low:75.83
Close:77.02
Loading ...

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Business Wire
·
28 Feb

Forbes and U.S. News & World Report Agree: HealthEquity is One of America’s Best Places to Work

GlobeNewswire
·
27 Feb

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire
·
27 Feb

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Business Wire
·
27 Feb

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

Business Wire
·
27 Feb

Coles share price lifts off on dividend boost

MotleyFool
·
27 Feb

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

Business Wire
·
27 Feb

F5 Unveils Industry’s First Converged Application Delivery and Security Platform for the Hybrid Multicloud Infrastructures of the AI Era

Business Wire
·
27 Feb

How Agree Realty, Peoples Bancorp, And Robert Half Can Put Cash In Your Pocket

Benzinga
·
26 Feb

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

GlobeNewswire
·
26 Feb

Indonesia, Apple Agree on Terms to Lift iPhone 16 Ban, Bloomberg News Reports

Tempo
·
25 Feb

Meridian Energy and NZAS Agree on 50MW Demand Reduction for Winter 2025

TIPRANKS
·
25 Feb

OS Therapies Forms Drug Conjugates Unit, Reviews Options for Tunable ADC, Drug Conjugates Platforms

MT Newswires Live
·
24 Feb

ADC Therapeutics Is Maintained at Overweight by Stephens & Co.

Dow Jones
·
24 Feb

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

GlobeNewswire
·
24 Feb

ADC Therapeutics price target raised to $8 from $6 at Stephens

TIPRANKS
·
24 Feb